News Headlines Article

5 drugs to watch: What Bay Area biotechs are testing on patients right now
San Francisco Business Times

A new batch of human studies that started in July could be promising for Bay Area drug-development companies and the patients who may benefit from the experimental treatments. The three-stage clinical trial hurdle to win Food and Drug Administration approval for a drug, however, is high. By some measures, only one in three drugs that make their way into Phase II trials advance to the final phase.